{
    "clinical_study": {
        "@rank": "63767", 
        "acronym": "INNOVATION", 
        "arm_group": [
            {
                "arm_group_label": "Infliximab group", 
                "arm_group_type": "Experimental", 
                "description": "Infliximab with MTX treatment"
            }, 
            {
                "arm_group_label": "Classic DMARDs treatment group", 
                "arm_group_type": "Active Comparator", 
                "description": "Classic DMARDs treatment\uff08MTX \u3001LEF \u3001HCQ \u3001 LEF \uff09"
            }
        ], 
        "brief_summary": {
            "textblock": "A prospective, multi-centric, cohort study to observe the efficacy difference between\n      intensive classic DMARDs and Infliximab(IFX) with methotrexate(MTX) treatment in sever\n      rheumatoid arthritis(RA) 28 joints disease activity score>5.1(DAS28>5.1) patients with poor\n      prognostic factors.Primary objective is compare the difference of clinical remission rate\n      between classic DMARDs and Infliximab with MTX treatment in severe RA patients with poor\n      prognostic factors at week 30."
        }, 
        "brief_title": "Infliximab and Classic DMARDs in the Rheumatoid Arthritis Patients", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis\uff08RA\uff09", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary objective is compare the difference of clinical remission rate between classic\n      conventional disease-modifying antirheumatic drugs(DMARDs) and Infliximab with\n      methotrexate(MTX) treatment in severe RA patients with poor prognostic factors at week 30.\n\n      Secondary objectives are  compare the differences of laboratory measurements, clinical\n      remission rate, function score and imageological evaluation between classic DMARDs and\n      Infliximab with MTX treatment in severe RA patients with poor prognostic factors at week 14,\n      30, 54 and 102.\n\n      Infliximab arm\uff1aInfliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then\n      once every 8 weeks, MTX>7.5mg per week. To observe the results at week 14, 30, 54 and 102\n      after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after\n      remission for a period of time in good economic condition patients while receiving MTX with\n      hydroxychloroquine(HCQ) or leflunomide(LEF) in poor economic condition patients.\n\n      Classic DMARDs treatment arm\uff1a Classic DMARDs treatment combination of 2 or 3 drugs, 2-drugs\n      combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF\n      or Thunder God Vine for total 30 weeks.\n\n      Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder\n      God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF\n      after remission for a period of time.\n\n      Study is divided into three stages First stage: day -7 to 0\n\n        1. Sign informed consent;\n\n        2. Examine and verify the inclusion and exclusion criteria;\n\n        3. Collect the data of demographic characteristics, history of present illness, signs and\n           symptoms, history of previous illness and concomitant medicine, personal history,\n           allergic history, injury and surgery history;\n\n        4. Data of laboratory examinations: Rheumatoid Factor(RF),anti citrullinated protein\n           antibodies(ACPA) ;\n\n        5. Safety data: vital signs, blood routine examination, biochemical test;\n\n        6. Efficacy data: Erythrocyte Sedimentation Rate(ESR), C Reactive Protein(CRP),  28 joints\n           disease activity score(DAS28 score), Simplified disease activity index(SDAI) score,\n           American College Of Rheumatology(ACR)/European League Against Rheumatism(EULAR)\n           remission ,Sharp van der Heijde scoring(SHARP) score, Magnetic Resonance Imaging(MRI)\n           score, Health Assessment Questionnaire(HAQ) score;\n\n      Second stage: week 0 to week 30, follow-up duration I The subjects are randomized assigned\n      to achieve experimental or control treatment for 30 weeks and follow up at week 2, 6, 14, 22\n      and 30.\n\n        1. The follow up items are same at week 2 and week 22: signs and symptoms, ESR, CRP;\n\n        2. The follow up items at week 6: signs and symptoms, blood routine examinations,\n           biochemical test, ESR, CRP;\n\n        3. The follow up items at week 14: signs and symptoms, ESR, CRP, DAS28 score, SDAI score,\n           ACR/EULAR remission, SHARP score, MRI score, HAQ score;\n\n        4. The follow up items at week 30: signs and symptoms, RF, ACPA, blood routine\n           examinations, biochemical test, ESR, CRP, DAS28 score, SDAI score, ACR/EULAR remission,\n           SHARP score, MRI score, HAQ score.\n\n      Third stage: Week 30 to 102, follow-up duration II After 30 weeks treatment the subjects are\n      into 72 weeks follow-up duration, the follow up will be conducted at week 38, 46, 54 and\n      102.\n\n        1. The follow up items are same at week 38 and 46: signs and symptoms, ESR, CRP;\n\n        2. The follow up items: signs and symptoms, blood routine examinations, biochemical test,\n           ESR, CRP, DAS28 score, ACR/EULAR remission, SHARP score, MRI score, HAQ score;\n\n        3. The follow up items at week 102: signs and symptoms, RF, ACPA, blood routine\n           examinations, biochemical test, ESR, CRP, DAS28 score, SDAI score, ACR/EULAR remission,\n           SHARP score, MRI score, HAQ score."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Able and willing to provide written informed consent and to comply with the  study\n             protocol\n\n          2. Age is from 18 to 70 years old\n\n          3. To accord with the diagnostic criteria of ACR/EULAR 2010 and the course of disease is\n             less than 2 years;\n\n          4. Active RA, DAS28 score is above 5.1\n\n          5. At least has one poor prognostic factor including:(1)functional\n             limitations,(2)extra-articular manifestation,(3)positive RF or Anti-Cyclic\n             Citrullinated Peptide(CCP) antibody ,(4)X- ray confirmed bone erosion.\n\n        Exclusion Criteria:\n\n          1. Received Infliximab or other biologics treatment previously;\n\n          2. Abnormal liver function, the level of alanine aminotransferase(ALT) and aspartate\n             amino transferase(AST) is higher than 3 times of  upper limit of normal (ULN);\n\n          3. Renal dysfunction, the level of serum creatinine is higher than 1.5 times of ULN;\n\n          4. Receive live virus or bacterial vaccination currently or 4 weeks before recruitment\n             into the study;\n\n          5. Previously affected by tuberculosis or with positive tuberculin test result;\n\n          6. Has history of lymphoproliferative disease such as lymphoma or suspected\n             lymphoproliferative disease through signs and symptoms such as  lymphadenectasis in\n             posterior cervical triangle, interclavicular or supratrochlear,  or splenomegaly\n             (more than 2 cm below the ribs);\n\n          7. History of multiple sclerosis or other demyelinating diseases of central nervous\n             system;\n\n          8. Be allergic to experimental drug or with serious allergic constitution;\n\n          9. Malignancies excluding cured skin basal cell carcinoma or carcinoma in situ of\n             cervix;\n\n         10. Systemic active infection, HIV infection or active Hepatitis B or Hepatitis B virus\n             carriers;\n\n         11. With serious medical diseases such as cardiac insufficiency (), myocardial  ischemia,\n             serious arrhythmia, renal insufficiency, serious liver dysfunction,  significant\n             hematological system diseases, hypercortisolism, uncontrollable  hypertension and\n             diabetes mellitus;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01915537", 
            "org_study_id": "INNOVATION"
        }, 
        "intervention": [
            {
                "arm_group_label": "Infliximab group", 
                "description": "Infliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then once every 8 weeks, MTX>7.5mg per week. To observe the results at week 14, 30, 54 and 102 after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after remission for a period of time in good economic condition patients while receiving MTX with HCQ or LEF in poor economic condition patients.", 
                "intervention_name": "Infliximab group", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Classic DMARDs treatment group", 
                "description": "Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.\nEffective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time.", 
                "intervention_name": "Classic DMARDs treatment group", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Infliximab", 
                "Antirheumatic Agents"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "poor prognosis", 
            "severe RA", 
            "infliximab"
        ], 
        "lastchanged_date": "August 1, 2013", 
        "location": [
            {
                "contact": {
                    "email": "jinwei7310@163.com", 
                    "last_name": "Jinwei Chen, Bachelor", 
                    "phone": "0731-85295155"
                }, 
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "state": "Hunan", 
                        "zip": "410011"
                    }, 
                    "name": "The Second Xiangya Hospital of Central South University"
                }, 
                "investigator": {
                    "last_name": "Jinwei Chen, Bachelor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "wuzhenbiao@fmmu.edu.cn", 
                    "last_name": "Zhenbiao Wu, Ph.D", 
                    "phone": "+86 29 84775355"
                }, 
                "facility": {
                    "address": {
                        "city": "Xi An", 
                        "country": "China", 
                        "state": "Shanxi", 
                        "zip": "710032"
                    }, 
                    "name": "XIJING Hospital"
                }, 
                "investigator": {
                    "last_name": "Zhenbiao Wu, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "tjweiwei2003@hotmail.com", 
                    "last_name": "Wei Wei, Master", 
                    "phone": "022-60362912"
                }, 
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300052"
                    }, 
                    "name": "Tianjin medical university general hospital"
                }, 
                "investigator": {
                    "last_name": "Wei Wei, Master", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Cohort Study to Observe the Difference of Efficacy Between Infliximab With Methotrexate and Classic DMARDs in the Severe Rheumatoid Arthritis Patients With Poor Prognosis", 
        "overall_contact": {
            "email": "zhangxiao20130724@163.com", 
            "last_name": "Xiao Zhang, Ph.D", 
            "phone": "+86 139 222 55387"
        }, 
        "overall_official": {
            "affiliation": "Director", 
            "last_name": "Xiao Zhang, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The rate of subjects achieving DAS<2.6 at week 30", 
            "measure": "The rate of subjects achieving DAS<2.6", 
            "safety_issue": "No", 
            "time_frame": "at week 30"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01915537"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zhang,  Xiao, M.D.", 
            "investigator_full_name": "Zhang,  Xiao, M.D.", 
            "investigator_title": "Director", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The rate of subjects achieving DAS<2.6 at week 14, 54 and 102", 
                "measure": "The rate of subjects achieving DAS<2.6", 
                "safety_issue": "No", 
                "time_frame": "at week 14, 54 and 102"
            }, 
            {
                "description": "The rate of subjects achieving SDAI<3.3 at week 14, 30, 54 and 102;", 
                "measure": "The rate of subjects achieving SDAI<3.3", 
                "safety_issue": "No", 
                "time_frame": "at week 14, 30, 54 and 102"
            }, 
            {
                "description": "The rate of subjects achieving ACR/EULAR remission at week 14, 30, 54 and 102;", 
                "measure": "The rate of subjects achieving ACR/EULAR remission", 
                "safety_issue": "No", 
                "time_frame": "at week 14, 30, 54 and 102"
            }, 
            {
                "description": "MRI score at week 14, 30, 54 and 102;", 
                "measure": "MRI score", 
                "safety_issue": "No", 
                "time_frame": "at week 14, 30, 54 and 102"
            }, 
            {
                "description": "The HAQ score at week 14, 30, 54 and 102;", 
                "measure": "The HAQ score", 
                "safety_issue": "No", 
                "time_frame": "at week 14, 30, 54 and 102"
            }, 
            {
                "description": "The SHARP score at week 14, 30, 54 and 102", 
                "measure": "The SHARP score", 
                "safety_issue": "No", 
                "time_frame": "at week 14, 30, 54 and 102"
            }, 
            {
                "description": "The level of ESR at week 2, 6, 14, 22, 30, 54 and 102", 
                "measure": "The level of ESR", 
                "safety_issue": "No", 
                "time_frame": "at week 2, 6, 14, 22, 30, 54 and 102"
            }, 
            {
                "description": "The level of CRP at week 2, 6, 14, 22, 30, 54 and 102", 
                "measure": "The level of CRP", 
                "safety_issue": "No", 
                "time_frame": "at week 2, 6, 14, 22, 30, 54 and 102"
            }
        ], 
        "source": "Zhang,  Xiao, M.D.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Central South University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Tianjin Medical University General Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Xijing Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Zhang,  Xiao, M.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}